Nuvation Bio Relocates HQ to New York City
Ticker: NUVB · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1811063
Complexity: simple
Sentiment: neutral
Topics: corporate-governance, administrative-change, relocation
TL;DR
**Nuvation Bio moved its HQ to New York City, signaling potential strategic shifts.**
AI Summary
Nuvation Bio Inc. filed an 8-K on January 8, 2024, to report a change in its principal executive offices from 357 Tehama Street, San Francisco, CA 94103 to 1500 Broadway, Suite 1401, New York, NY 10036. This move signifies a potential strategic shift or expansion for the pharmaceutical preparations company, which could impact operational efficiency and access to talent. Investors should note this change as it might reflect broader corporate strategy or a move closer to key financial hubs.
Why It Matters
A company's headquarters location can influence its operational costs, access to talent, and proximity to investors and partners, all of which can impact its long-term success and stock performance.
Risk Assessment
Risk Level: low — The filing primarily reports an administrative change of address, which typically carries minimal direct financial risk.
Analyst Insight
Investors should monitor future filings for Nuvation Bio Inc. to see if this headquarters relocation is part of a larger strategic initiative, such as new partnerships or a shift in business focus, which could impact the company's long-term prospects.
Key Players & Entities
- Nuvation Bio Inc. (company) — the registrant filing the 8-K
- 357 Tehama Street, Floor 3, San Francisco, CA 94103 (address) — Nuvation Bio's former business address
- 1500 Broadway, Suite 1401, New York, NY 10036 (address) — Nuvation Bio's new principal executive offices
- January 8, 2024 (date) — date of the earliest event reported in the 8-K
- NUVB (ticker) — trading symbol for Nuvation Bio Inc. Class A Common Stock
Forward-Looking Statements
- Nuvation Bio Inc. will experience increased operational costs due to the move to New York City. (Nuvation Bio Inc.) — medium confidence, target: 2025-01-08
- The relocation to New York will enhance Nuvation Bio's access to a broader talent pool in the pharmaceutical and financial sectors. (Nuvation Bio Inc.) — medium confidence, target: 2025-01-08
FAQ
What was the specific date of the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 8, 2024.
What is Nuvation Bio Inc.'s new principal executive office address, as stated in the filing?
Nuvation Bio Inc.'s new principal executive office address is 1500 Broadway, Suite 1401, New York, NY 10036.
What was Nuvation Bio Inc.'s previous business address before this change?
Nuvation Bio Inc.'s previous business address was 357 Tehama Street, Floor 3, San Francisco, CA 94103.
What is the trading symbol for Nuvation Bio Inc.'s Class A Common Stock?
The trading symbol for Nuvation Bio Inc.'s Class A Common Stock is NUVB.
Under which item of Form 8-K was this information primarily filed?
This information was primarily filed under Item 5.02, 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers', though the content provided only details an address change.
Filing Stats: 878 words · 4 min read · ~3 pages · Grade level 9.6 · Accepted 2024-01-08 16:17:00
Key Financial Figures
- $0.0001 — which registered Class A Common Stock, $0.0001 par value per share NUVB The New Yo
- $11.50 — of Common Stock at an exercise price of $11.50 per share NUVB.WS The New York Stoc
- $770,000 — Common Stock with an aggregate value of $770,000. The option vests monthly over a three-
- $40,000 — igible to receive an annual retainer of $40,000 for his service on the Board. If Dr. Ma
Filing Documents
- d685245d8k.htm (8-K) — 27KB
- 0001193125-24-004426.txt ( ) — 185KB
- nuvb-20240108.xsd (EX-101.SCH) — 4KB
- nuvb-20240108_def.xml (EX-101.DEF) — 14KB
- nuvb-20240108_lab.xml (EX-101.LAB) — 23KB
- nuvb-20240108_pre.xml (EX-101.PRE) — 15KB
- d685245d8k_htm.xml (XML) — 6KB
02
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 8, 2024 the Board of Directors (the " Board ") of Nuvation Bio Inc. (the " Company "), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Robert Mashal, M.D. to fill a vacant Board seat and to serve as a Class II director, with an initial term expiring at the Company's 2026 Annual Meeting of Stockholders. As of the date of this filing, Dr. Mashal has not been appointed to serve on any committee of the Board. Dr. Mashal, age 64, has served as a consultant to the life sciences industry since April 2020 through Robert Mashal LLC and Beacon Prince Partners. From November 2016 to April 2020, he was the Global Head of Strategy for the Immunology and Oncology franchises at Sanofi, a global pharmaceutical and healthcare company. Prior to November 2016, Dr. Mashal worked as CEO of NKT Therapeutics and Alinea Pharmaceuticals, two venture capital-backed life sciences firms. Prior to that, he was a partner at Boston Millennia Partners, a private equity firm, where he was on the Board of Directors of GlycoFi, CardioMEMS, and Sapphire Therapeutics. Prior to that, he served as a Program Executive at Vertex Pharmaceuticals, where he was on the Joint Steering Committee for the Vertex-Novartis kinase collaboration, and was a consultant at McKinsey & Company. Prior to McKinsey, Dr. Mashal was a board-certified medical oncologist and received his training in internal medicine at the University of California, San Francisco, and in oncology at the Dana-Farber Cancer Institute. Dr. Mashal received a B.A. in Natural Sciences and an M.D. from Johns Hopkins University. The Board has determined that Dr. Mashal qualifies as an independent director under the independence requirements set forth under Section 303A.02 of the New York Stock Exchange listing rules. There are no